Organogenesis (NASDAQ:ORGO) Earns “Buy” Rating from BTIG Research

Organogenesis (NASDAQ:ORGO)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a research note issued on Thursday,Benzinga reports. They currently have a $8.00 price target on the stock. BTIG Research’s price objective suggests a potential upside of 249.34% from the company’s previous close.

Other equities analysts have also issued reports about the company. Wall Street Zen raised Organogenesis from a “hold” rating to a “buy” rating in a research note on Sunday, March 8th. Weiss Ratings raised shares of Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research report on Friday, February 27th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Organogenesis Trading Down 5.4%

ORGO stock opened at $2.29 on Thursday. The company has a quick ratio of 3.32, a current ratio of 3.62 and a debt-to-equity ratio of 0.04. The company has a market cap of $294.59 million, a price-to-earnings ratio of 28.63 and a beta of 1.43. The business has a fifty day simple moving average of $3.36 and a 200-day simple moving average of $4.28. Organogenesis has a 52 week low of $2.28 and a 52 week high of $7.08.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, February 26th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. The firm had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%. On average, equities research analysts expect that Organogenesis will post -0.07 EPS for the current year.

Insider Buying and Selling at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll acquired 10,000 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was acquired at an average price of $2.67 per share, with a total value of $26,700.00. Following the transaction, the director directly owned 225,707 shares in the company, valued at approximately $602,637.69. This represents a 4.64% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 33.00% of the company’s stock.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds have recently made changes to their positions in the business. State of Alaska Department of Revenue bought a new stake in shares of Organogenesis during the third quarter valued at about $25,000. Quarry LP bought a new position in Organogenesis in the 3rd quarter valued at about $25,000. Flagship Harbor Advisors LLC acquired a new position in Organogenesis during the 4th quarter valued at about $34,000. Federated Hermes Inc. raised its position in shares of Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after buying an additional 2,953 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Organogenesis during the 2nd quarter worth about $45,000. Institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.